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AbstrACt
Introduction The incidence of severe postpartum 
haemorrhage (PPH) that requires blood transfusion is on 
the increase. Fibrinogen levels have been shown to drop 
early and significantly during PPH, which is associated 
with worse outcomes. Early fibrinogen replacement 
could potentially improve outcomes. No studies have 
investigated the clinical impact of early cryoprecipitate 
transfusion in PPH. Prior to performing a full- scale trial, 
a pilot study is needed to determine feasibility of the 
intervention and recruitment.
Methods ACROBAT is a cluster- randomised pilot 
study with a qualitative evaluation. Four large London 
maternity units are randomised to either the intervention 
or control group. The intervention group will adapt their 
major obstetric haemorrhage procedures to administer 
cryoprecipitate early for primary PPH. The control group 
will retain their standard of care.
We include women at >24 weeks gestation who are 
actively bleeding within 24 hours of delivery and for whom 
transfusion of red blood cells (RBCs) has been started. We 
exclude women who decline blood transfusions in advance 
or have inherited Factor XIII or fibrinogen deficiency. Due 
to the emergency nature of the intervention, informed 
consent for administering the intervention is waived.
The primary objective is to assess the feasibility of 
administering cryoprecipitate within 90 min of RBC 
request, as compared with standard treatment where 
cryoprecipitate is given later or not at all. Secondary 
objectives include the feasibility of recruitment and 
data collection, reasons for and barriers to consent, 
preliminary maternal clinical outcomes, identification of 
the optimal infrastructure pathways for study delivery, and 
acceptability of the intervention and outcomes.
Ethics and dissemination The trial has approvals 
from the London—Brighton & Sussex Research Ethics 
Committee (ref. 18/LO/2062), the Confidentiality Advisory 
Group (ref. 18/CAG/0199) and Health Research Authority 
(IRAS number 237959). Data analysis and publication of 
manuscripts will start in Q3 2020.
trial registration number ISRCTN12146519.
IntroduCtIon
Postpartum haemorrhage (PPH) is a common 
cause of mortality, morbidity and long- term 
disability worldwide.1 The incidence of severe 
PPH that requires treatment with blood 
transfusion has increased in the UK, due to 
increasing maternal age, obesity, increased 
obstetric intervention and higher rates of 
strengths and limitations of this study
 ► This is the first randomised controlled trial (RCT) as-
sessing the early administration of cryoprecipitate 
compared with standard care in severe postpartum 
haemorrhage (PPH).
 ► We have chosen a pilot cluster RCT design rather 
than an individually randomised study to assess if it 
is feasible to administer cryoprecipitate early during 
PPH, to avoid contamination, but this could be seen 
as a limitation.
 ► In this study, we have obtained substantial input 
from patient and public members into the consent 
processes, and our nested qualitative evaluation will 
explore how the consent materials and processes 
are received by participating women and healthcare 
professionals.
 ► In this study, we will also survey various stakehold-
ers (patient representatives and various clinical spe-
cialists) to prioritise outcome measures that should 
be reported in future trials for treatment of severe 
PPH.
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caesarean section.2 The increase in PPH incidence has 
seen a significant rise in the maternal morbidity rate, with 
severe PPH accounting for ~77% of all maternal intensive 
care unit admissions between 2003 and 2012.3 Further, 
women who survive severe PPH are likely to suffer more 
long- term morbidity compared with other types of 
obstetric complications.4
Several studies have demonstrated consistently that 
fibrinogen levels drop early and significantly during PPH 
and that a low level of fibrinogen (<2 g/L) is an indepen-
dent predictor for morbidity5 and requirement for addi-
tional red blood cell (RBC) transfusion.6 7 Despite this, a 
UK study of women with PPH who had received massive 
transfusion (≥8 RBC units) showed that only 60% of 
women were administered cryoprecipitate, and this was 
given after a mean of eight RBC units transfusion.8 The 
benefits of early correction of coagulation abnormalities 
(of which fibrinogen is part) in patients with bleeding 
have recently been demonstrated by several trials.9–11 
However, to date, there have been no clinical trials to vali-
date if early replacement of fibrinogen with cryoprecip-
itate in severe PPH is better than the current standard, 
where cryoprecipitate is given if fibrinogen levels drop 
to <2 g/L or if the woman receives massive transfusion.12 
The reasons for this include the delay in obtaining blood 
results and the practical limits of how quickly cryopre-
cipitate can be administered to patients, considering 
the thawing and transportation time. A more proactive 
approach to correct fibrinogen early, by administering 
cryoprecipitate as soon as the need for transfusion is iden-
tified, may improve outcomes for women. However, prior 
to performing a large interventional trial, a pilot study 
is needed to identify barriers to recruitment, assess feasi-




A cluster- randomised, controlled, non- blinded, pilot trial 
with additional qualitative evaluation.
setting
Participants will be recruited at four maternity units 
within London (UK): the Royal London Hospital, 
Newham University Hospital, Whipps Cross University 
Hospital and Homerton University Hospital. Two of these 
maternity units are randomised to the intervention group 
and two to the control group (see figure 1).
objectives and endpoints
Primary objective
To assess the feasibility of administering cryoprecipitate 
early (within 90 min of request of the first RBC unit) 
in pregnant women who are actively bleeding and who 
require blood transfusion for treatment of bleeding 
within 24 hours of delivery, as compared with standard 
treatment, where cryoprecipitate is given later or not at 
all.
Secondary objectives
 ► To assess the feasibility of recruitment and data 
collection and the proportion of participants treated 
according to allocation.
 ► To assess reasons for consent, or refusal of consent, 
for data collection.
 ► To obtain preliminary data on event rates in both 
intervention and control groups to help estimate the 
sample size and intracluster correlation, and to esti-
mate the impact of early cryoprecipitate transfusion 
on clinical outcomes and haemostatic markers, to 
inform the definitive trial.
 ► To identify the optimal infrastructure pathway and 
personnel to deliver the intervention, and to identify 
and recruit patients in the intervention group within 
and outside working hours (ie, transfusion laboratory 
or clinical areas).
 ► To evaluate the acceptability of the study intervention 
and outcomes to clinicians and participating women.
Primary endpoint
Proportion of women who were administered cryoprecip-
itate within 90 min of the request of the first unit of RBC 
transfusion, in the intervention and control groups. The 
first request of RBC units will be documented as the time 
the laboratory is called to request RBC units, or the time 
when the first unit of RBC is removed from the remote 
blood fridges (where available).
Secondary endpoints
 ► Proportion of women who were recruited to the trial, 
and for whom complete outcomes were obtained.
 ► Proportion of women who were approached and did 
not consent to the trial.
 ► Proportion of women who were approached and 
agreed to routine data collection.
 ► Proportion of women where there was a study protocol 
violation.
 ► Preliminary clinical outcome data will be collected 
up to hospital discharge or 28 days after recruitment 
(whichever is sooner), and these include: mortality 
(all- cause); hysterectomy; surgical interventions to 
stop haemorrhage such as, but not limited to, intra-
uterine balloon tamponade, uterine artery emboli-
sation, uterine artery ligation etc.; the total number 
of units transfused within 24 hours and until hospital 
discharge (number of units for RBC, fresh frozen 
plasma, cryoprecipitate and platelet transfusion); 
transfusion- related reactions; length of stay in high 
dependency unit, intensive care units and hospital; 
requirement for mechanical ventilation; any organ 
failure; symptomatic thrombotic events (ie, pulmo-
nary embolism, and/or deep vein thrombosis and 
arterial thrombotic events, and maternal fatigue as 
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Figure 1 CONSORT flowchart.
measured by the Multidimensional Fatigue Inventory 
(MFI) questionnaire.
 ► Occurrence of symptomatic thrombotic events (arte-
rial and venous) up to 3 months after recruitment.
study population
As this is a cluster randomised controlled trial (RCT), 
all women who fulfil the inclusion criteria will be treated 
according to the allocated group in the respective mater-
nity unit.
Inclusion criteria: pregnant women at >24 weeks gesta-
tion, who are actively bleeding within 24 hours of delivery 
and for whom at least one unit of RBC has been started or 
transfused to stem active bleeding.
Exclusion criteria: women who decline blood transfu-
sion in advance and women with inherited Factor XIII 
or fibrinogen deficiency. These are routinely treated 
according to a separate, dedicated protocol.
recruitment
Consent procedures
Due to the urgency of the intervention, the cluster 
design and the fact that the occurrence of PPH cannot 
be adequately predicted, advance consent for adminis-
tering intervention will be waived. However, women on 
both groups will be approached by the research team 
for written, informed consent to collect their routine, 
de- identified data, up to hospital discharge or 28 days after 
delivery—whichever is first. In addition to this routine 
data, they will also be asked for consent to complete the 
MFI questionnaire; readiness to be contacted for a qual-
itative interview, collection of residual blood samples 
from the hospital laboratories; and a follow- up telephone 
call 3 months post- discharge. For women who die or 
are discharged from the hospital before being identi-
fied and approached for their consent and who cannot 
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be contacted after discharge, routine, de- identified data 
will be collected from the medical notes up to hospital 
discharge or 28 days after delivery—whichever is first. 
Additionally, assent and parental consent will be obtained 
for participants under the age of 16 years and consultee 
consent will be obtained for an eligible woman without 
the capacity to consent. Women will be informed that they 
have the right to refuse consent for data collection, as 
well as to withdraw consent previously given, at any time, 
without giving a reason, and that this will not affect their 
subsequent care. If they withdraw consent, data collected 
up to the point of withdrawal will be retained in the study. 
Participant information sheets and consent forms used 
for this pilot study are available as online supplementary 
files 1-6.
Information posters and leaflets are displayed in ante-
natal clinics to inform women on each study site. These 
provide study aims, contact details and sources for further 
information. All recruitment materials have been devel-
oped with significant input from an East London patient 
and public involvement (PPI) group (see the Discussion 
section).
Screening procedures
Given the design of the study, eligible women are identi-
fied after they have received treatment for PPH. To this 
end, the research team will consult obstetric transfusion 
records and delivery records on a daily basis. Additionally, 
ongoing training and information campaigns for clinical 
obstetric, anaesthetic and laboratory teams are in place 
to ensure both treatment adherence and support to the 
research team in identifying eligible participants.
Randomisation procedures
We will randomly allocate two hospitals each to the inter-
vention and control groups, through randomisation at a 
ratio of 1:1, prior to the start of recruitment (see figure 1).
study interventions and assessments
Intervention group: two pools of cryoprecipitate will be 
thawed as soon as possible by the transfusion laboratory 
and transfused to eligible women within 90 min of the 
request of the first RBC unit.
Control group: control group will administer standard 
transfusion therapy, where cryoprecipitate is adminis-
tered if the fibrinogen result is <2 g/L, or if a woman has 
received massive transfusion (ie, >8 RBC transfusion) in 
accordance with national guidelines.13 14
Assessments and data collection: clinical data will be 
collected from medical notes and records, with the excep-
tion of the patient- reported fatigue questionnaire. Case 
report forms (CRFs) will be completed by the clinical 
research team on each maternity unit and entered into 
a bespoke, secure online study database using a unique 
study ID for each participant.
Qualitative data will be collected through interviews 
with 10–15 participating women, depending on data 
saturation, to explore their opinions and experiences of 
study procedures, ∼2–3 months after their recruitment. 
Where needed, the interviewer will connect women with 
birth debriefing support structures at the hospital where 
they gave birth. Additionally, ∼10 healthcare professionals 
involved in the delivery of the study will be interviewed in 
order to explore perspectives and experiences with the 
delivery of the intervention. All interviews will be subject 
to separate written informed consent. Interviews will be 
audio‐recorded, with participant consent, and conducted 
using an interview schedule.
Follow- up: women will be followed up until discharge 
or 28 days after delivery, whichever is sooner. Additionally, 
there will be one follow- up phone call at 3 months post-
delivery enquiring about any thromboembolic events, 
provided that women have given informed consent for 




The calculation of the sample size is based on an assump-
tion of the incidence of PPH requiring any blood trans-
fusion being 0.5%–4.5%,3 15 and for this trial, it was 
estimated that 2% of the women would be eligible for 
the pilot. The total number of deliveries at four hospi-
tals is over 24 000 per year, indicating that ~400 women 
per year will go on to develop PPH and require a blood 
transfusion.
For the pilot study, 200 eligible women will be recruited, 
split into ~100 per group. This sample size will enable 
us to construct a 95% CI for the proportion of women 
administered cryoprecipitate within 90 min of bleeding 
onset with a precision ±8 percentage points if the esti-
mated proportion were 0.8, that is, from 0.71 to 0.87, 
Wilson approach.16 For the consent rate, given a fixed 
n=200 and with a p=0.5, the 95% CI will range between 
0.43 and 0.57. Although we will aim to recruit 100 women 
per treatment group, the imbalance between the inter-
vention and control groups can be accommodated. Preci-
sions obtained will be similar even in the extreme scenario 
in which one arm recruits 140 and the other 60 patients.
Statistical analysis
We will summarise continuous variables using mean and 
SD or median and IQR as appropriate. We will provide 
point estimates of proportions for categorical variables 
along with corresponding exact 95% CI. We will explore 
differences in recruitment, acceptance and consenting 
rates between the two groups of the trial but avoid formal 
statistical tests. Given the limited number of clusters 
randomised (n=4), it is crucial to assess if there is any 
systematic selection bias that can be suspected after exam-
ining baseline clinical and demographic characteristics 
of participating women in the intervention and standard 
care groups. Additionally, this low number of clusters will 
not be enough to provide a robust estimation of intra-
cluster correlation coefficient (ICC). Thus, the estima-
tion obtained using pilot- trial data will be compared with 
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Table 2 Progression criteria
Feasibility objectives and 
related data to be collected
Go criteria to proceed to full 
trial
Criteria to reassess and 
adjust full trial protocol Stop criteria
Study population
1. Consent rates of eligible 
women
Rate >25% of eligible women 
agreeing to participate.
Rate between 11% and 24% 
women agreeing to participate
Rate <10% of eligible women 
agreeing to participate
Study outcomes
2. Proportion of women in either 
intervention or control group for 
whom the allocated treatment is 
adhered to.
Adherence to allocated 
treatment in >80% of study 
sample.
Adherence to allocated 
treatment in between 51% 
and 79% of study sample.
Adherence to allocated 
treatment in <50% of study 
sample.
RCT processes
3. Collection of data on clinical 
outcomes.
Complete data available of 
>80% of study sample.
Missing data between 21% 
and 49% of study sample.
Data missing of >50% of 
study sample.
RCT, randomised controlled trial.
Table 1 Schedule of enrolment, interventions and assessments
Timepoint Pre- study
Study period
Delivery Post- intervention, pre- discharge Follow- up
0 0–28 days
Consent* to
28 days 3 months
Enrolment
  Allocation (cluster randomisation) X
  Eligibility screen X
  Informed consent X
Interventions
  Intervention clusters: 2 pools of early 
cryoprecipitate
X
  Standard haemorrhage protocol X
Assessments
  Demographics and medical history X
  Documentation of medical and surgical 
interventions
X
  Clinical outcomes and adverse events X
  Symptomatic thrombotic events X X
  Haemostatic markers X
  MFI questionnaire X
  Qualitative interviews X
*Alternatively, if conditions for waiver are fulfilled, routine data can be collected in the absence of written informed consent.
MFI, multidimensional fatigue inventory.
ICC estimations available in the literature. The analysis 
of clinical outcomes will only be exploratory, and we will 
avoid formal statistical tests to compare the two groups. 
We will also focus on assessing data collection procedures, 
to obtain an estimation of data quality and the degree of 
missingness.
Progression criteria
Table 2 below outlines the main criteria that will be 
considered to assess the feasibility of a full- scale RCT. 
In addition, our qualitative findings will also be used to 
support the decision- making around progression to a full- 
scale trial. For example, if a progression criterion outlined 
in table 2 does not meet the threshold for progression, 
but we have developed a qualitative understanding of why 
this occurred and how it could be improved, then it may 
still be possible to proceed with the full trial.
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trial management and oversight
Data management
All data management will be undertaken by the Queen 
Mary University of London (QMUL). Standard operating 
procedures will be in place for the collection and handling 
of data. All study data will be entered directly by trained 
and delegated local research staff into a secure, bespoke 
electronic trial database set up and hosted by epiGenesys, 
University of Sheffield. User accounts will be allocated and 
managed centrally by the trial coordinator and restricted 
to appropriate site level access. Data collected on the forms 
and entered onto the electronic database will only identify 
the participants by a unique trial number. No identifiable 
data will be stored on the trial database.
Trial management
The trial is managed and run by the Barts Research Centre 
for Women’s Health trials office at QMUL. The trials office 
is responsible for safety reporting, coordination of trial 
committees, statistical analysis and reporting, trial moni-
toring, database management and case report form design.
Trial oversight
The project steering committee (PSC) has been established 
to oversee and monitor the trial conduct and patient safety. 
The committee is chaired by an independent consultant 
anaesthetist (Dr Matthew Wilson, University of Sheffield), 
with four other independent members, including a consul-
tant obstetrician (Prof Asma Khalil), a consultant haema-
tologist (Dr Susan Robinson), a statistician (Mr Baptiste 
Leurent) and a lay representative (Ms Ngawai Moss). The 
PSC provides overall supervision of the trial and ensures 
that it is being conducted according to the protocol, good 
clinical practice and relevant regulations. This committee 
also monitors trial progress in relation to recruitment, data 
capture and completeness, protocol adherence and devia-
tions and subject withdrawals. The committee meets every 6 
months. The PSC is also responsible for reviewing the trial 
data throughout the study and assessing whether there are 
any safety issues that need to be brought to the attention of 
the sponsor, or any ethical reasons why the trial should not 
continue. Given the low risk of the study intervention and 
that it is non- blinded, no separate data safety monitoring 
committee will be established. The sponsor retains the right 
to audit the study, including any study site or central facility.
Safety reporting
In addition to adverse maternal outcomes specified as 
secondary clinical outcomes, other adverse events will be 
documented from intervention to discharge using CRFs. 
Any events fulfilling the criteria for seriousness (fatal, 
life- threatening, prolonging hospitalisation, resulting in 
persistent or significant disability or incapacity) will be 
reported to the central trials office within 24 hours of the 
site becoming aware of the event. Exceptions to the require-
ment for reporting as serious adverse events (SAEs) have 
been formulated due to the nature of the condition: hospi-
talisations of fewer than seven nights are not reportable as 
prolongations, and PPH and pre- eclampsia do not require 
SAE reporting. We will also exclude events not directly 
related to the mother’s medical care (such as prolonged 
hospital stay of the mother due to the baby’s admission to 
intensive care or due to social reasons). SAEs will be reviewed 
by the chief investigator and summarised in reports to the 
PSC and the research ethics committee (REC). Any SAEs 
that is considered related to the intervention and that are 
unexpected will be reported to the sponsor and REC within 
expedited timelines.
Patient and public involvement
Due to the trial design, the inability to predict in advance 
many of the women that experience a PPH, and the fact 
that obtaining consent at the time of bleeding could delay 
a life- saving treatment, we opted for a waiver of advance 
consent to administering intervention. Prior to adopting 
this consent model, we consulted with Katie’s Team, a 
well- established East London women’s health PPI group17 
to discuss various aspects of this trial and in particular the 
timing of consent and the level of information deemed 
appropriate for antenatal discussion. After deliberation, 
the PPI group accepted that full advance consent would 
cause unnecessary anxiety to women and their families, 
as the majority of women admitted for delivery would not 
experience severe haemorrhage requiring blood transfu-
sion support. Since the risk associated with administering 
cryoprecipitate are very low, and cryoprecipitate is already 
part of standard care (although later on in the course of 
bleeding), most PPI representatives accepted that full 
consent postintervention would be appropriate. The group 
did suggest that advertising the trial through displaying 
posters and leaflets in antenatal clinics would allow inter-
ested women to learn about the study, provide an oppor-
tunity to discuss the study with the research team and/or 
read the study leaflet prior to admission into hospital for 
delivery. PPI members also gave valuable input on wording 
and presentation of information (including a graphical 
representation of the intervention), helping to develop 
a more patient- centred patient information sheet. The 
qualitative research embedded within this pilot study will 
prove integral in evaluating how the consent materials and 
processes were received in practice.
dIsCussIon
No RCT has previously assessed early cryoprecipitate trans-
fusion in severe PPH in comparison with standard care.18 
In this trial, we chose to perform a cluster RCT rather 
than an individually randomised study for several reasons. 
The first is the risk of contamination whereby a patient 
who is randomised to standard treatment might end up 
receiving the intervention because it has been made avail-
able through the introduction of the research protocol and 
affected physician equipoise. Second, in the UK maternity 
units, the management of severe PPH is heavily protoco-
lised and is delivered by a variety of medical staff including 
midwives, obstetricians, anaesthetists and theatre staff. 
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Hence, a cluster RCT, where recruiting centres adopt a 
clearly defined protocol for emergency management, 
which is uniform across an entire obstetric unit, offers the 
best way to answer our question without compromising care 
in an emergency situation.
The sample size of the cluster in a pilot stage is another 
important factor to consider. It will allow us to estimate the 
95% CIs with a precision of ±8 percentage points. Once 
these CIs are obtained it will be possible to decide whether 
it is feasible to deliver cryoprecipitate early, so as to upscale 
to a full trial. Since our primary outcome is to determine 
whether we can administer cryoprecipitate within 90 min 
in the intervention arm, the hospitals participating in the 
feasibility study were selected for the following reasons: (1) 
they are busy obstetric units catering for a diverse popula-
tion of pregnant women; (2) they have varying distances 
between transfusion laboratories and labour wards which 
would affect the speed of delivering blood components to 
women experiencing obstetric haemorrhage, and thus test 
different transfusion systems and infrastructure; and finally 
(3) all are research- active institutions with the capacity to 
deliver a trial within an emergency setting. Furthermore, 
prior to initiating this study, transfusion major haemor-
rhage protocols on all sites were assessed and all sites were 
following the national guidelines.12 13
In a future full- scale trial, there are many potentially rele-
vant primary outcomes that can be used, and our pilot study 
results will aid in identifying outcomes for a future trial 
that are both meaningful and feasible to collect reliably. In 
addition, our group is also surveying various stakeholders 
(including patient representatives as well as various clinical 
specialists) to prioritise outcomes for future trials for the 
treatment of severe PPH requiring transfusion; this is work 
ongoing in parallel to this study.
trial status
Protocol version 4.0, 6 September 2019. The start date 
of participant recruitment: 4 March 2019. The project 
recruitment completion date: 29 February 2020. The end 
of follow- up: 31 May 2020.
EthICs And dIssEMInAtIon
The trial was granted NHS Research Ethics approval 
from the London—Brighton & Sussex Research Ethics 
Committee (reference number 18/LO/2062), the Confi-
dentiality Advisory Group for access to and collection of data 
without prior consent (reference number 18/CAG/0199) 
and Health Research Authority approval (IRAS number 
237959). All subjects participating in the trial will provide 
written informed consent where possible as highlighted in 
the methods section above. Specific exceptions to this have 
been approved by the Confidentiality Advisory Group. Any 
changes to the protocol are subject to a formal amendment 
and may not be implemented prior to the approval by the 
Research Ethics Committee.
Consent for publication
All relevant data from this study will be submitted to peer- 
reviewed journals for publication following the completion 
of the study in line with sponsor publication policy. Data will 
be captured for all study participants, and no patient iden-
tifiable data will be used in any publications. The sponsor 
retains the right to review all publications prior to submis-
sion or publication. Responsibility for ensuring accuracy 
of any publication from this study is delegated to the chief 
investigator. Authorship will be assigned in compliance 
with International Committee of Medical Journal Editors 
(ICMJE) guidelines.
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